Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. The company is developing DNTH103, a monoclonal antibody, which is in clinical-stage trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Dianthus Therapeutics, Inc.

Stifel Nicolaus analyst Alex Thompson CFA maintained a Buy rating on Dianthus Therapeutics today and set a price target of $133.00. Thompson CFA co...

Dianthus Therapeutics (DNTH) Receives a Rating Update from a Top Analyst

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Dianthus Therapeutics (DNTH), Elanco Animal Health (...

Analysts’ Top Healthcare Picks: Dianthus Therapeutics (DNTH), Elanco Animal Health (ELAN)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Hims & Hers Health (HIMS) and Dianthus Therapeutic...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	DNTH	$108.10	+0.23%	638.56K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	DNTH	$108.10	+0.2%	638.56K
3
4
5
6

DNTH

Get Dianthus Therapeutics, Inc. Data in Excel

Get Dianthus Therapeutics, Inc. Data in Excel